Date: 2015-04-23
Type of information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in Science Translational Medicine
Company: arGEN-X (The Netherlands - Belgium) de Duve Institute/UCL (Belgium)
Product: ARGX-115
Action
mechanism: monoclonal antibody. ARGX-115 blocks the activity of GARP, a novel immune checkpoint involved in TGF-β1 activation.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 23, 2015, arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, and de Duve Institute / Université Catholique de Louvain (UCL) / WELBIO (BE) announced the publication of new data showing that the preclinical therapeutic antibody ARGX-115 blocks the activity of GARP, a novel immune checkpoint involved in TGF-β1 activation. These findings were published in Science Translational Medicine and suggest potential for the antibody candidate in cancer immunotherapy. “Combining the expertise of the de Duve Institute/UCL/WELBIO in cancer immunology with arGEN-X’s proprietary SIMPLE AntibodyTM platform led to the discovery of ARGX-115, a highly differentiated monoclonal antibody that inhibits the novel immune checkpoint GARP,” commented Hans de Haard, Chief Scientific Officer of arGEN-X. “We believe there is potential for ARGX-115 as a future cancer immunotherapy as it inhibits specific downstream effects of regulatory T-cells (Tregs), a known contributor to cancer progression through the inhibition of anti-tumor immune responses. Additionally, there may be possibilities to use ARGX-115 in combination with tumor vaccines or other therapeutic antibodies in order to improve the efficiency of cancer immunotherapy regimens.” \"Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo\" Cuende J. et al., Science Translational Medicine, 2015 April 22, Vol 7, Issue 284, p. 284ra56 (DOI: 10.1126/scitranslmed.aaa1983
